Literature DB >> 8805766

Group sequential designs for monitoring survival probabilities.

D Y Lin1, L Shen, Z Ying, N E Breslow.   

Abstract

In the present paper we derive the asymptotic joint distribution of the Nelson-Aalen estimators for the cumulative hazard function (or the Kaplan-Meier estimators for the survival function) calculated at different (possibly random) calendar time points of a survival study. This result is used to develop group sequential designs for clinical trials in which patients are enrolled over an extended period and the survival probability at a given failure time point is the parameter of primary interest. The proposed designs allow monitoring the survival probability (or probabilities) at interim looks so that the study can be terminated when there is sufficient evidence for a positive or negative result. A detailed illustration is provided with a problem from the National Wilms Tumor Study Group, which motivated this research.

Entities:  

Mesh:

Year:  1996        PMID: 8805766

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  13 in total

1.  A computationally simple bivariate survival estimator for efficacy and safety.

Authors:  Denise Scholtens; Rebecca A Betensky
Journal:  Lifetime Data Anal       Date:  2006-08-18       Impact factor: 1.588

2.  Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer.

Authors:  Feng Gao; Guoqiao Wang; Jingqin Luo; Jingxia Liu; Ling Chen; Chengjie Xiong
Journal:  Stat Biopharm Res       Date:  2019-04-18       Impact factor: 1.452

3.  Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.

Authors:  Michael J Martens; Brent R Logan
Journal:  Lifetime Data Anal       Date:  2019-11-15       Impact factor: 1.588

4.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

5.  Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.

Authors:  Lili Zhao; Jeremy M G Taylor; Scott M Schuetze
Journal:  Stat Med       Date:  2012-02-23       Impact factor: 2.373

Review 6.  Group sequential tests for long-term survival comparisons.

Authors:  Brent R Logan; Shuyuan Mo
Journal:  Lifetime Data Anal       Date:  2014-07-23       Impact factor: 1.588

7.  Single-Arm Phase II Group Sequential Trial Design with Survival Endpoint at a Fixed Time Point.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2014-05-27       Impact factor: 1.452

8.  The use of group sequential designs with common competing risks tests.

Authors:  Brent R Logan; Mei-Jie Zhang
Journal:  Stat Med       Date:  2012-09-04       Impact factor: 2.373

9.  Two-stage phase II survival trial design.

Authors:  Jianrong Wu; Li Chen; Jing Wei; Heidi Weiss; Aman Chauhan
Journal:  Pharm Stat       Date:  2019-11-21       Impact factor: 1.234

10.  Design of Phase II cancer trials evaluating survival probabilities.

Authors:  L Douglas Case; Timothy M Morgan
Journal:  BMC Med Res Methodol       Date:  2003-04-03       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.